Nasal involvement is the most commonly observed otolaryngologic feature in GPA, with symptoms often mimicking chronic rhinosinusitis. Destructive otolaryngologic manifestations in granulomatosis with ...
Two serious adverse events occurred, both of which resolved fully, and no deaths or life-threatening adverse events were reported. Prolonged treatment with tamoxifen was well tolerated in boys with ...
Key outcomes included high ILD prevalence, postmyopathic PPF in 13.5% of the cohort, higher rates of rapidly progressive ILD and transplantation in postmyopathic PPF, greater rituximab use in PPF, and ...
At 4 weeks post-surgery, the patient's anterior tibialis and quadriceps strength had improved from 2 to 3 out of 5 preoperatively to 4 out of 5. Routine fluoroscopy and high-magnification ...
A qualitative matrix analysis allowed for the development of implementation strategies to improve the efficiency and effectiveness of the system. Researchers from the US identified an ideal system to ...
Efgartigimod demonstrated clinically meaningful benefit and acceptable tolerability in patients with double-seronegative generalized MG. Rare Disease Advisor, a trusted source of medical news and ...
Life expectancy in DMD has improved over time. Previous estimates pointed to a life expectancy of 25 years, with more recent data reporting a life expectancy of 31.7 years (95% CI, 27.4-36.0). 3,4 A ...
The management of PI underwent a transformative shift in 1979 with the US Food and Drug Administration (FDA) approval of intravenous immunoglobulin (IVIg), which became the standard therapy for ...
Kerrie Walters, who has MS, and her service dog, Wooldridge, at home in Grants Pass, Oregon (Credit: Jennifer Butler Photography) Kerrie Walters first heard of PoNS in a chance encounter with TV ...
Several factors can contribute to the suppression of bone marrow erythropoiesis in infants with HDFN, including maternal antibodies, intrauterine transfusion, and simple transfusion. The suppression ...
Intravenously administered zaltenibart was shown to be safe and effective in phase 2 clinical trials. Enrollment is under way to recruit patients for a phase 3 study designed to assess intravascular ...
The authors used individual patient data from garadacimab trials (phase 2 and 3 VANGUARD) and published summary data from the phase 3 HELP trial for lanadelumab. Garadacimab may offer superior ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results